SEATTLE, WA — June 23, 2002 —
Initiating migraine treatment with almotriptan (Axert) within the first hour of attack onset offers the best possibility of attaining a pain-free response, researchers reported here June 22 at the annual meeting of the American Headache Society.
“Our findings indicate that Axert therapy begun while the migraine pain is mild is effective in achieving pain-free responses,” said investigator Andrew Dowson, MD, director of King’s Headache Services, King’s College Hospital in London, United Kingdom, “This is important news for migraine sufferers around the world, that we can nip this problem in the bud and avoid pain and disability associated with migraine.”
Dr. Dowson and his investigative team made a post hoc analysis of data from a double-blind, randomized and placebo-controlled trial of Axert 12.5 mg and Imitrex (sumatriptan) 100 mg assessing the effects of early versus late initiation of treatment. They studied the data for indications of a sustained pain free response (pain-free at two hours with no recurrence from two to 24 hours) to treatment.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!